CHOROIDAL THICKNESS AFTER FULL-FLUENCE AND HALF-FLUENCE PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
OBJECTIVE
To compare clinical outcomes after full-fluence and half-fluence photodynamic therapy (PDT) in chronic central serous chorioretinopathy, focusing on changes in subfoveal choroidal thickness (SFCT) using enhanced depth imaging optical coherence tomography.


METHODS
Retrospective, comparative interventional case series.


RESULTS
In the full-fluence (n = 25) and half-fluence groups (n = 43), SFCT decreased from 351 ± 70 μm and 362 ± 63 μm at baseline to 276 ± 65 μm and 322 ± 70 μm at 3 months and remained at 267 ± 66 μm and 318 ± 76 μm at 12 months, respectively (all P < 0.001, for each comparison with baseline). The change in SFCT was greater in the full-fluence group than in the half-fluence group (P = 0.001). In the half-fluence group, SFCT was thicker in the treated eye than in the fellow eye (P = 0.045), whereas in the full-fluence group, the difference in SFCT was not significant (P = 0.209). Best-corrected visual acuity and central retinal thickness improved after PDT in both groups (all P < 0.001). However, the differences between the groups were not significant (P = 0.873 and P = 0.124, respectively).


CONCLUSIONS
The results at 1 year show that full-fluence PDT reduces SFCT more than half-fluence PDT, and that SFCT after half-fluence PDT was still thicker than that in the fellow eye. The clinical implications of this finding for long-term outcomes including recurrence rate remain to be elucidated.
Department of Ophthalmology, Seoul National University Hospital, Seoul, South Korea.
Baek-Lok
BL
Oh
Hyeong Gon
HG
Yu
D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy*; D002829:Choroid / Q000473:pathology*; D002908:Chronic Disease; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage; D011166:Porphyrins / Q000008:administration & dosage; D012160:Retina / Q000473:pathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin